Thursday, 28 March, 2024
HomeMedico-LegalUK competition authority fines Aspen Pharmacare R45m

UK competition authority fines Aspen Pharmacare R45m

The UK Competition and Markets Authority (CMA) has imposed a £2.1m (R45m) fine on Aspen Pharmacare for entering into an illegal agreement that allowed it to hike the price of a life-saving drug, reports Business Day. Aspen said in August that it had reached a settlement and admitted liability for entering into an agreement relating to the supply of fludrocortisone in the UK, which is used to treat adrenal insufficiency.

Three companies, Aspen, Tiofarma, and Amilco, have now admitted to taking part in an anti-competitive agreement, the CMA said. After the agreement was struck, the price of fludrocortisone supplied to the UK’s National Health Service (NHS) increased by up to 1,800%.

Aspen reached an agreement with the CMA in August, with the £2.1m being the maximum penalty that could be imposed. The CMA said on Thursday the settlement sum had been paid.

The report says the UK competition authorities had launched the investigation in 2017, investigating the supply of two drugs, fludrocortisone and dexamethasone, although the probe into the latter was later dropped.

 

[link url="https://www.businesslive.co.za/bd/companies/healthcare/uk-authority-gives-aspen-maximum-fine-over-life-saving-drug/?utm_source=&utm_medium=email&utm_campaign=JSE+hits+best+level+in+over+four+months+on+global+stimulus+hopes+%7C+CPS+business+rescue+should+continue%2C+says+practitioner+%7C+SA%E2%80%99s+population+has+grown+by+nearly+2-million+in+two+years&utm_term=http%3A%2F%2Fwww.businesslive.co.za%2Fbd%2Fcompanies%2Fhealthcare%2Fuk-authority-gives-aspen-maximum-fine-over-life-saving-drug%2F"]Full Business Day report[/link]

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.